Your fact-checks will appear here
Professional organisation
No explicit, formal endorsements or dedicated recommendations for repurposed antiparasitic drugs appear in the recent guideline summaries and updates from the National Comprehensive Cancer Network (NC...
(Grade Group 4–5 or Gleason ≥8) with a deceptively low serum PSA should trigger more aggressive staging and consideration of treatment intensification rather than reassurance; modern imaging (includin...
Three orally administered CDK4/6 inhibitors—, and —are widely accepted first‑line partners to endocrine therapy in and have broadly similar efficacy for progression‑free survival in trials, though rea...
Major oncology guideline bodies (NCCN, ESMO, ASCO) have not adopted ivermectin as a recommended cancer treatment; available sources report only early-phase trials and preclinical work, with one active...